Axogen (NASDAQ: AXGN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Axogen reported 35 open-market sales of 493,343 shares ($17.1m) and 0 open-market purchases, by 12 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 2 September 2026 | Tyndall Joseph A. | Director | Open-market sale, 10b5-1 plan | −3,500 | $49.70 | 10,650 | Form 4 |
| 11 August 2026 | Wendell Amy McBride | Director | Option exercise, 10b5-1 plan | +13,353 | $14.85 | 121,329 | Form 4 |
| 11 August 2026 | Wendell Amy McBride | Director | Open-market sale, 10b5-1 plan | −13,353 | $48.42 | 107,976 | Form 4 |
| 10 August 2026 | Began Marc A | EVP & General Counsel | Option exercise, 10b5-1 plan | +67,500 | $8.16 | 117,635 | Form 4 |
| 10 August 2026 | Began Marc A | EVP & General Counsel | Open-market sale, 10b5-1 plan | −67,500 | $47.35 | 50,135 | Form 4 |
| 7 August 2026 | Weiler Kathy Johnson | Director | Open-market sale, 10b5-1 plan | −14,150 | $45.30 | 0 | Form 4 |
| 19 June 2026 | Burke William P. Mr. | Director | Option exercise | +14,150 | — | 14,250 | Form 4 |
| 19 June 2026 | Tyndall Joseph A. | Director | Option exercise | +14,150 | — | 14,150 | Form 4 |
| 19 June 2026 | Thomas Paul | Director | Option exercise | +18,867 | — | 32,395 | Form 4 |
| 19 June 2026 | Weiler Kathy Johnson | Director | Option exercise | +14,150 | — | 14,150 | Form 4 |
| 19 June 2026 | Levine Alan M | Director | Option exercise | +14,150 | — | 50,893 | Form 4 |
| 19 June 2026 | Wendell Amy McBride | Director | Option exercise | +14,150 | — | 107,976 | Form 4 |
| 19 June 2026 | Johnson John | Director | Option exercise | +14,150 | — | 14,150 | Form 4 |
| 8 May 2026 | Wendell Amy McBride | Director | Option exercise | +1,647 | $14.85 | 95,473 | Form 4 |
| 8 May 2026 | Wendell Amy McBride | Director | Open-market sale | −1,647 | $42.60 | 93,826 | Form 4 |
| 7 May 2026 | Quackenbush Doris | Sales VP | Open-market sale | −3,878 | $43.51 | 92,416 | Form 4 |
| 7 May 2026 | Hartley Lindsey Marie | CFO | Option exercise | +2,500 | $8.20 | 63,234 | Form 4 |
| 7 May 2026 | Hartley Lindsey Marie | CFO | Open-market sale | −478 | $43.67 | 62,756 | Form 4 |
| 7 May 2026 | Hartley Lindsey Marie | CFO | Option exercise | +2,963 | $8.27 | 65,719 | Form 4 |
| 7 May 2026 | Hartley Lindsey Marie | CFO | Open-market sale | −573 | $43.67 | 65,146 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Axogen page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.